An Observational Study of Patients With Malignant Lymphomas Treated With MabThera SC in Everyday Clinical Practice.
Phase of Trial: Phase IV
Latest Information Update: 22 Aug 2019
Price : $35 *
At a glance
- Drugs Rituximab (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Sponsors Roche
- 20 Aug 2019 Status changed from active, no longer recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 31 Jul 2018 Planned End Date changed from 1 Jul 2019 to 31 Jul 2019.